Email: dvtustudies@duke.edu | Telephone: 919-971-5649
Active Clinical Trials
Dr. Walter is leading a study designed to obtain blood from Duke employees who are recovering from SARS-CoV-2 infection for the purposes of neutralizing antibody assay validation. No NCT number.
Dr. Walter is leading a Phase 1 Dose Escalation trial to evaluate the safety and immunogenicity of an inactivated chikungunya virus vaccine in healthy adults. Further information about this study can be found at clinicaltrials.gov. The NCT number is NCT06669208.
Dr. Smith is leading a study to assess the safety of simultaneous vaccination with mRNA COVID-19 vaccine and other vaccines in young children aged 6 Months to <5 years. Further information about this study can be found at clinicaltrials.gov. The NCT number is NCT06038617.
Dr. Smith is leading a study to assess the safety, tolerability, and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy infants. Further information about this study can be found at clinicaltrials.gov. The NCT number is NCT06524414.
Dr. Smith is leading a study to assess the safety, tolerability, and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy toddlers. Further information about this study can be found at clinicaltrials.gov. The NCT number is NCT06531538.
Dr. Swamy is leading a study to assess the safety of simultaneous versus sequential administration of mRNA COVID-19 vaccine and inactivated influenza vaccine (IIV) in pregnant people. Further information about this study can be found at clinicaltrials.gov. The NCT number is NCT06503900.
Dr. Walter is leading a Phase 1 study to assess the safety and immunogenicity of a single dose of an investigational mRNA influenza vaccine in healthy adults age 18 to 49 years. Further information about this study can be found at clinicaltrials.gov. The NCT number is NCT05755620.
Drs. Woods and Walter are leading a registry study to enroll healthy persons for future participation in influenza, SARS-CoV-2, and other respiratory pathogen vaccination studies and influenza challenge studies.